ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 1437

    Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
  • Abstract Number: 1438

    Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
  • Abstract Number: 1439

    Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
  • Abstract Number: 1440

    Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
  • Abstract Number: 1441

    Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases
  • Abstract Number: 1442

    Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
  • Abstract Number: 1443

    Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
  • Abstract Number: 1444

    Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
  • Abstract Number: 1445

    Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
  • Abstract Number: 1446

    Trauma Is Associated with Flares in Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 1447

    Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
  • Abstract Number: 1448

    Virtual Visits versus Face-to-Face Visits for Rheumatoid Arthritis (RA): Comparison of Treat to Target (TTT) Adherence in 18 US Rheumatology Practices
  • Abstract Number: 1449

    Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
  • Abstract Number: 1450

    Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-based Cohort of Patients with Rheumatoid Arthritis
  • Abstract Number: 1451

    Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
  • « Previous Page
  • 1
  • …
  • 97
  • 98
  • 99
  • 100
  • 101
  • …
  • 132
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology